drugset / Trial / NCT06092242
The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer
Phase 2
Not yet recruiting
50 enrolled
The Second Affiliated Hospital of Shandong First Medical University
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of TAS-102 combined with bevacizumab as first-line therapy in patients with advanced colorectal cancer who could not tolerate or did not receive combined chemotherapy
Timeline
- Start
- 2023-10-15
- Primary completion
- 2025-10-15
- Completion
- 2027-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | TAS-102 | Small molecule | 35 mg/m2 | Oral |